Gilead Sciences surprised investors with stronger-than-expected Q2 results, driven by a surge in its HIV portfolio. The biotech giant reported earnings of $2.01 per share, beating estimates, while revenue climbed to $7.1 billion—a $200 million year-over-year increase. The standout performer was its newly approved twice-yearly HIV prevention injection, Lenacapavir, which saw rapid adoption, contributing to a 7% growth in HIV segment sales ($5.1 billion). Management raised full-year guidance, projecting adjusted earnings of $7.95–$8.25 per share and revenue of $28.3–$28.7 billion, sending shares up nearly 3% in after-hours trading.
Mixed Performance Across Divisions
While the HIV business thrived, cell therapies declined 7% to $485 million amid stiff competition. Oncology drug Trodelvy grew 14% to $364 million, offsetting some weakness in hepatitis C treatments. Despite conservative 2025 forecasts aligning with analyst expectations, Gilead’s stock has gained 46% over the past year, reflecting investor confidence in its HIV innovation pipeline.
